Skip to main navigation Skip to search Skip to main content

A Phase II Randomized,Observer Blind,Multicenter Study of GlaxoSmithKline Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine (MMRV) Versus ProQuad, According to a One Dose Schedule, Both Administered Subcutaneously 12-14 Months..

Project: Research

Project Details

StatusFinished
Effective start/end date02/21/08 → 12/31/09

Funding

  • GlaxoSmithKline: $2,500.00